Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Basel Sachs 18th BEF Forum (October 2018)
14 slides from Cantargia Ab's conference presentation, October 2018
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: IL-1 blockade in cancer - Recent supportive clinical data
IL-1 blockade in cancer- Recent supportive clinical data CANTOS trial Canakinumab phase 3 trials • Canakinumab (Novartis) Adjuvant NSCLC • Reduced lung cancer incidence After surgery, no mets, placebo control by 67 % and death by 77 %. 1500 patients, recruitment ongoing Completion 2021/22 First line
Slide 4: CAN04 (nidanilimab) vs Canakinumab
CAN04 (nidanilimab) vs Canakinumab Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04: • Binds the common signaling receptor and counteracts both ligands • Induce killing via the immune system (ADCC) 4
Slide 5: Medical need and IL1RAP
Medical need and IL1RAP • Cantargia founded based on: • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP - antitumor effects • Patents on antibody therapy against IL1RAP • Primary indications. NSCLC and pancreatic cancer • Biomarker studies ongoing, identify patients most likely to re
Slide 6: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Phase I/IIa trial - NSCLC and pancreatic cancer • Norway, Denmark, Netherlands and Belgium • Well renowned centres (Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo) • 15 patients treated, good safety • NSCLC
Slide 7: Cantargia at a glance
Cantargia at a glance Current owners (Jun 30, 2018) • Specialized in antibody therapy/immunology, with initial focus on Sunstone 9.0% oncology 1st AP fund 6.9% • Granted IP - therapeutic target IL1RAP and drug candidate • Lead antibody CAN04 (nidanilimab) in clinical development Avanza Pension 6.0%
Slide 8: Cantargia pipeline
Cantargia pipeline Project Discovery Preclinical Phase I Phase Il Phase III Commercial phase phase phase CANO4 Non-small cell lung cancer Pancreatic cancer Leukemia CANxx Autoimmune and inflammatory diseases * @antargia
Slide 9: CAN04 attacks several cell types in the tumor
CAN04 attacks several cell types in the tumor 9
Slide 10: Inflammation and metastasis
Inflammation and metastasis • Cancer cells (seeds) needs a good soil to form a metastasis • The IL-1 system (inflammation) can provide such environment (soil) A tumor can create its own ”seed and soil” 10
Slide 11: NSCLC CAN04/Cisplatin combination
NSCLC CAN04/Cisplatin combination Control CAN04 Cisplatin Combination C is p la t in 5 m g /k g Animals 20 % (Tumor) 0% 50 % (Toxicity) 20 % (Toxicity) 2500 withdrawn T u m o r v o lu m e (m m ) 3 2000 Tumor N/A 14% 18% 52 % 1500 reduction ** 1000 500 Comment Highest tumor Best safety Highest toxici
Slide 12: IL1RAP - additional potential indications to leverage the value of our asset
IL1RAP - additional potential indications to leverage the value of our asset • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, C
Slide 13: Significant value inflection points ahead
Significant value inflection points ahead 2018 • Preclinical data (immuno-oncology effects, combinations etc) • Phase I clinical data (Q4 2018) • Initiation of Phase IIa portion of the clinical trial (Q4 2018) • US regulatory and clinical strategy 2019/2020 • Clinical progress and Phase IIa results
Slide 14: Cantargia summary
Cantargia summary • Lead candidate antibody CAN04 in clinical trials against cancer • Double mechanism of action • Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis) • Direct effects on tumor cells and tumor microenvironment • Recent external validation of pathway
Cantargia — Basel Sachs 18th BEF Forum (October 2018) on 6ix